Primary axillary (armpit) hyperhidrosis can be a disabling condition, affecting the occupational and social activities of patients and is associated substantially with reduced quality of life. It affects between approximately 0.5% and 2.5% of the population. The mechanism of hyperhidrosis is thought to be hyperstimulation of the eccrine sweat glands.
In hyperhidrosis, Botox® acts by targeting these glands to block sweat production.
Studies have demonstrated the effect of one set of injections can reduce sweat production by upto 80% within 4 weeks and the treatment is effective for 7-10 months depending on doses used. Long term safety and efficacy has been demonstrated in a number of studies. Furthermore treatment of axillary hyperhidrosis with Botox® results in significant improvement of quality of life measures.
The cost of this procedure is £375.